MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide-based therapies for endocrine and metabolic disorders. Its pipeline targets conditions where long-acting or precision peptides may improve on existing hormone treatments. With no commercial products yet, value hinges on clinical progress rather than product sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -23.9 | — |
| Q2 2025 | 0 | — | -19.4 | — |
| Q3 2025 | 0 | — | -21.6 | — |
| Q4 2025 | 0 | — | -22.1 | — |
| Q1 2026 | 0 | — | -23.5 | — |
| Q2 2026 | 0 | — | -37.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Innospec Inc. (IOSP), Stock Yards Bancorp, Inc. (SYBT), Clover Health Investments, Corp. (CLOV), NewAmsterdam Pharma Company N.V. (NAMS), Chagee Holdings Limited (CHA), Blackbaud, Inc. (BLKB)